Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists
Nicolas Levoin, Olivier Labeeuw, Stéphane Krief et al. · Bioorganic & Medicinal Chemistry · 2013
Cited by 13 works. doi:10.1016/j.bmc.2013.05.035
Authors
- Nicolas Levoin
- Olivier Labeeuw
- Stéphane Krief
- Thierry Calmels
- Olivia Poupardin
- Isabelle Berrebi‐Bertrand
- Jeanne‐Marie Lecomte
- Jean-Charles Schwartz
- Marc Capet
References
- MUSCLE: a multiple sequence alignment method with reduced time and space complexity
- MAFFT version 5: improvement in accuracy of multiple sequence alignment
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor
- Cloning and Functional Expression of the Human Histamine H3Receptor
- Protein Flexibility in Ligand Docking and Virtual Screening to Protein Kinases
- Virtual Screening Workflow Development Guided by the “Receiver Operating Characteristic” Curve Approach. Application to High-Throughput Docking on Metabotropic Glutamate Receptor Subtype 4
- Structure of the human histamine H1 receptor complex with doxepin
- The histamine H3 receptor: from discovery to clinical trials with pitolisant
- Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)
- The Role of Transmembrane Helix 5 in Agonist Binding to the Human H3 Receptor